Skin Cancer Evaluation. Simplified.
Joined July 2017
- Tweets542
- Following254
- Followers210
- Likes68
The only FDA-cleared automated solution for skin cancer detection, and it fits in your hand. DermaSensor uses AI + Elastic Scattering Spectroscopy to help physicians assess lesions at the point of care. Objective. Fast. Built for real practices. Request a demo, link in bio.
DermaSensor, Inc. retweeted
A great reminder that preventive care and regular skin checks should not be overlooked. Planning ahead can make it easier to stay on top of routine screenings and skin health throughout the year.
Before schedules fill up, get your annual physicals, screenings, and skin checks on the calendar.
A little planning now = easier preventive care before the holiday rush.
Need a provider? Use the DermaSensor Physician Finder (link in bio) to find one near you.
For cancer survivors, staying proactive about skin health brings extra reassurance. In this patient testimonial, hear how simple the DermaSensor assessment felt and how it added confidence to their skin check. Find a physician near you at the link in bio.
Summer's over, but sun damage can linger. As fall physicals ramp up, make skin checks part of the visit, especially when a suspicious lesion comes up.
DermaSensor pairs elastic scattering spectroscopy + AI for an immediate result at point of care.
dermasensor.com
Primary care is often where suspicious skin lesions are first noticed. DermaSensor brings objective, real-time data into the exam room to support risk assessment when it matters most. Learn more via the link in bio.
Skin cancer is one of the most common cancers, making awareness and early detection more important than ever.
More practices are adding DermaSensor, and the clinical value speaks for itself: 96% sensitivity, FDA cleared, non-invasive, immediate results. Objective skin cancer risk data at the point of care, without slowing down the visit. Link in bio to learn more.
Summer's ending, but UV damage doesn't. Repeated sunburns raise skin cancer risk, including melanoma. Watch for spots that are new, changing, or concerning. DermaSensor gives clinicians an AI-powered, non-invasive tool for real-time skin cancer risk assessment. Link in bio.
Health equity matters in skin cancer detection. DermaSensor's AI analyzes 47 wavelengths per lesion. DERM-SUCCESS study: 95.5% sensitivity overall, 96.5% in Fitzpatrick I-III, 92.2% in IV-VI. Innovation + evidence = equitable care. Link in bio.
#DermaSensor #HealthEquity
DermaSensor, Inc. retweeted
What if you could assess a mole for skin cancer risk in 30 seconds or less?
That's exactly what this Miami-based company does with its FDA-approved device. Learn more about how it works in our latest episode of the Miami Tech Pod.
🎧 Listen to the full episode — link in bio.
@DermaSensor @codyVsimmons
DermaSensor, Inc. retweeted
PCPs miss UP TO HALF of melanoma cases, and only 3-5% of biopsies are actually melanoma.
Learn how this Miami company is helping PCP's better detect skin cancer while also helping avoid unnecessary biopsies.
🎧 Listen to the full episode — link in bio.
@DermaSensor @codyVsimmons
DermaSensor, Inc. retweeted
He didn't start DermaSensor. He got the call in 2016, said yes, and didn't stop until the FDA said yes too.
Our cover story on @dermasensor
yespress.io/cody-simmons?utm… via Yespress
Technology continues to play an important role in expanding access to healthcare and improving efficiency.
